These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 3243980

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of ovarian tumor antigen NB/70K: monoclonal antibody assays for distinguishing ovarian cancer from other gynecologic disease.
    Knauf S.
    Am J Obstet Gynecol; 1988 May; 158(5):1067-72. PubMed ID: 3369485
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibody assays for measuring ovarian tumor antigen in blood. Detection of NB/70K in patients with ovarian cancer and nongynecologic diseases.
    Knauf S.
    Cancer; 1988 Sep 01; 62(5):922-5. PubMed ID: 3409174
    [Abstract] [Full Text] [Related]

  • 5. Selectivity for ovarian cancer of an improved serum radioimmunoassay for human ovarian tumor-associated antigen NB/70K.
    Knauf S, Taillon-Miller P, Helmkamp BF, Bonfiglio TA, Beecham JB.
    Gynecol Oncol; 1984 Mar 01; 17(3):349-55. PubMed ID: 6706232
    [Abstract] [Full Text] [Related]

  • 6. Clinical correlations of ovarian cancer antigen NB/70K: a preliminary report.
    Dembo AJ, Chang PL, Urbach GI.
    Obstet Gynecol; 1985 May 01; 65(5):710-4. PubMed ID: 3856794
    [Abstract] [Full Text] [Related]

  • 7. Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer.
    Petru E, Sevin BU, Averette HE, Koechli OR, Perras JP, Hilsenbeck S.
    Gynecol Oncol; 1990 Aug 01; 38(2):181-6. PubMed ID: 2387533
    [Abstract] [Full Text] [Related]

  • 8. A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients.
    Knauf S, Anderson DJ, Knapp RC, Bast RC.
    Am J Obstet Gynecol; 1985 Aug 01; 152(7 Pt 1):911-3. PubMed ID: 2411137
    [Abstract] [Full Text] [Related]

  • 9. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA, Kenemans P, Wobbes T, van Kamp GJ, de Bruijn HW, Thomas CM, Massuger LF, Schijf CP, Bon GG, Vermorken JB.
    Int J Cancer; 1991 Jan 21; 47(2):170-9. PubMed ID: 1988362
    [Abstract] [Full Text] [Related]

  • 10. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
    Bast RC, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC.
    Cancer; 1991 Oct 15; 68(8):1758-63. PubMed ID: 1913520
    [Abstract] [Full Text] [Related]

  • 11. An improved radioimmunoassay for human ovarian tumor antigen NB/70K.
    Knauf S, Taillon-Miller P.
    Gynecol Oncol; 1984 Sep 15; 19(1):67-73. PubMed ID: 6469090
    [Abstract] [Full Text] [Related]

  • 12. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H, Teshima K, Noda K.
    Gan To Kagaku Ryoho; 1984 Dec 15; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
    Shimizu Y, Akagaki E, Hirota K, Kono M, Miura S, Okudaira Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec 15; 37(12):2813-20. PubMed ID: 3866801
    [Abstract] [Full Text] [Related]

  • 16. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C.
    J Clin Oncol; 1993 Aug 15; 11(8):1506-10. PubMed ID: 8336189
    [Abstract] [Full Text] [Related]

  • 17. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
    Kobayashi H, Kawashima Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov 15; 41(11):1731-5. PubMed ID: 2574209
    [Abstract] [Full Text] [Related]

  • 18. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
    Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE.
    Obstet Gynecol; 1989 Sep 15; 74(3 Pt 1):384-7. PubMed ID: 2761916
    [Abstract] [Full Text] [Related]

  • 19. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
    Kimura E, Murae M, Koga R, Odawara Y, Nakabayashi Y, Yokoyama K, Nakata H, Totake T, Ochiai K, Yasuda M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov 15; 36(11):2121-8. PubMed ID: 6595320
    [Abstract] [Full Text] [Related]

  • 20. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC.
    J Natl Cancer Inst; 1993 Nov 03; 85(21):1748-51. PubMed ID: 8411259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.